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Abstract
Giant cell hepatitis associated with direct Coombs’ test-positive hemolytic anemia is a rare condition of 
childhood and the pathogenesis remains unclear. An autoimmune activation and loss of self-tolerance in 
these patients may be the underlying pathology related to the response of some of the patients to immuno-
suppressive treatment. Herein, we report the clinical presentation and course of three consecutive patients 
with this rare condition. We conclude that serum ferritin at diagnosis may be used for prediction of the 
outcome. (Turk J Hematol 2010; 27: 308-13)
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Özet
Direk Coombs’ testi pozitif hemolitik anemi ve dev hücreli hepatit birlikteliùi çocukluk çaù×nda pato-
genezi tam olarak ayd×nlat×lmam×ü nadir bir durumdur. Bu hastalar×n bir k×sm×n×n immünosupresif teda-
viye cevap veriyor olmas× otoimmün aktivasyon ya da kendi antijenlerine karü× tolerans kayb×n×n patogene-
zde sorumlu olabileceùini düüündürmektedir. Bu makalede bu nadir duruma sahip üç hastan×n baüvuru 
özellikleri ve takibi sunulmuütur. Baüvuru an×ndaki serum ferritin deùerinin hastan×n prognozunu belirle-
mede kullan×labileceùi önerilmiütir. (Turk J Hematol 2010; 27: 308-13)
Anahtar kelimeler: Dev hücreli hepatit, immün pozitif hemolitik anemi, direk Coombs’ testi, rituximab
Geliü tarihi: 5 May×s 2010    Kabul tarihi: 19 Aùustos 2010Introduction
Giant cell hepatitis (GCH) associated with direct 
Coombs’ test-positive autoimmune hemolytic ane-
mia (AIHA) is a rare, often lethal condition of early 
childhood with unknown pathogenesis. GCH-AIHA 
association is a distinct disorder from the more 
common GCH diagnosed in the neonatal period in 
association with infections, metabolic disorders 
and cholestasis [1-4]. Management of these patients 
is a challenge, carries poor response to immuno-
suppressive therapy and often progresses to fatal 
liver disease [1,5]. Tissue autoantibodies have been 
negative in most cases; however, these patients 
usually fail to respond to orthotopic liver transplan-
tation compared with other types of GCH found in 
children and have a high rate of GCH recurrence in 
the transplanted liver. This may suggest the pres-
ence of an as-yet undetermined circulating autoan-
tibody [1,2,6]. 
To our knowledge, 24 cases of GCH with AIHA 
have been reported [1-17]. The AIHA usually pre-
cedes the diagnosis of GCH by 1 week to 15 months 
(usually 1-2 months), and the hepatitis presents 
more insidiously [5,11]. Herein, we present the 
clinical presentation and course of three consecu-
tive patients with this rare condition with possible 
implications as to the etiopathogenesis. 
Case Reports 
Table 1 summarizes the clinical and laboratory 
characteristics of the study group.
Case 1
A two-month-old girl, the first child of parents 
with first-degree consanguinity, who presented with 
pallor was found to have direct Coombs’ test-posi-
tive hemolytic anemia and was placed on steroid 
treatment (2-10 mg/kg/day) and intravenous immu-
noglobulin (1 g/kg/day, for 2 days; 3 courses) in 
another center. The patient was transiently respon-
sive to attacks; however, she was found to have 
cytomegalovirus (CMV) IgM and CMV polymerase 
chain reaction (PCR) positivity (8800 copy/ml) at 
eight months of age and was placed on ganciclovir 
treatment. By the 14th day of antiviral treatment, she 
developed hypertransaminasemia and was referred 
to our center for further evaluation.
Physical examination revealed a jaundiced girl 
with body weight <3rd percentile and height 50-75th 
percentile. Liver and spleen were palpable 4 cm 
and 2 cm below the costal margins, respectively. 
The hemogram revealed hemoglobin (Hb): 10.3 g/
dl, hematocrit (Hct): 28.9%, white blood cells 
(WBC): 31.4x109 /L, thrombocyte: 244x109 /L, mean 
corpuscular volume (MCV): 94.1 fl, and red cell dis-
tribution width (RDW): 26.3. Reticulocytes were 
8.6% and peripheral blood smear exhibited poly-
chromasia, spherocytosis, anisocytosis, poikilocyto-
sis, and normoblastemia. The liver function tests 
revealed aspartate aminotransferase (AST): 2147 
(<37 IU/L), alanine aminotransferase (ALT): 2117 
(<41 IU/L), gamma-glutamyl transpeptidase (GGT) 
83.3 (5-36 IU/L), alkaline phosphatase (ALP): 949 
(<281 IU/L), total bilirubin: 62.7 (0.1-1.2 mg/dl), and 
conjugated bilirubin 62.1 (0-0.3 mg/dl). Serum IgA 
level was 116 mg/dl (8-80), IgG: 774 mg/dl (220-900) 
and IgM: 140 mg/dl (35-125). Viral serologies for 
hepatitis A, hepatitis B and hepatitis C were nega-
tive. CMV IgM and IgG were positive and CMV PCR 
was 951 copy/ml. Funduscopic examination for 
CMV infection was negative. Ganciclovir was con-
tinued until the result of the liver biopsy was avail-
able, which revealed giant cell transformation, por-
tal fibrosis, focal hepatocyte necrosis, lymphocytic 
infiltration, and hemosiderin accumulation in hepa-
tocytes and Kupffer cells, without any evidence of 
CMV involvement. The patient was diagnosed to 
have GCH-AIHA condition, and anti-nuclear anti-
body, anti-smooth muscle antibody, anti-liver kid-
ney microsomal antibody, and anti-cardiolipin and 
anti-phospholipid antibodies were found to be 
negative. Initial serum ferritin was measured as 
32078 ng/ml, and subsequently dropped to 4858 ng/
ml by the second week of admission. Serum triglyc-
eride was 547 (<200 mg/dl), cholesterol 132 (<200 
mg/dl) and plasma fibrinogen 360 mg/dl. The bone 
marrow aspiration revealed bi- and tri-nucleated 
normoblasts indicating erythroid hyperactivity and 
dyserythropoiesis with increased histiocytes with-
out any evidence of hemophagocytosis. 
Treatment was continued with 2 mg/kg methyl-
prednisolone, and azathioprine (1 mg/kg) was initi-
ated, in addition to cholestyramine for cholestasis 
and omega-3 for hyperlipidemia. She developed 
pneumonia with ground-glass appearance on tho-
rax computed tomography and CMV positivity 
Ünal et al.
Autoimmune hemolytic anemia-giant cell hepatitis  Turk J Hematol 2010; 27: 308-13 309recurred; ganciclovir was re-initiated. During the 
course, hepatic failure progressed with portal hyper-
tension and ascites, and rituximab (anti CD20) was 
initiated at 375 mg/m2/week, concomitant to ganci-
clovir. The patient died after the 3rd dose of ritux-
imab treatment, with intervening sepsis and hepatic 
coma, at 17 months of age.
Case 2 
A six-month-old boy presented to our center with 
pallor and jaundice. The personal history revealed a 
similar admission to a local hospital at the first 
month of life. He was thought to have prolonged 
jaundice and was transfused with packed red blood 
cells, and a second admission to the same hospital 
at three months of age with dark stools revealed 
disturbed liver function tests and prolonged coagu-
lation tests. Antibiotics, fresh frozen plasma and 
vitamin K were initiated and the patient was referred 
to our center at six months of age because of refrac-
tory illness.
The patient was the only child of a first-degree 
consanguineous couple, without history of any sib-
ling death. The physical examination revealed a 
jaundiced boy with hepatosplenomegaly, palpable 
8 cm and 6 cm below the costal margins, respec-
tively. Body weight and height were 3-10 p. The 
hemogram revealed Hb: 9 g/dl, Hct: 24.7%, WBC: 
6.7x109 /L, thrombocyte: 102x109 /L, MCV: 87.5 fl, 
and RDW: 16.6. Reticulocyte count was 4.2%. Direct 
Coombs’ test was positive. The liver function tests 
revealed AST: 309 IU/L, ALT: 92 IU/L, GGT: 29.9 IU/L, 
total bilirubin: 25.5 mg/dl, direct bilirubin 15.7 mg/dl, 
total protein: 5.86 g/dl, and albumin: 3.67 g/dl. 
Activated partial thromboplastin time (aPTT) and 
prothrombin time (PT) (international normalized 
ratio [INR]) were 46.6 sec (27.9-38.1) and 1.64 (0.86-
1.2), respectively. Serum IgA was 287 mg/dl (8-80), 
IgG: 1100 mg/dl (220-900) and IgM: 408 mg/dl (35-
125). Viral serologies for hepatitis A, hepatitis B and 
hepatitis C were negative. CMV IgM and IgG were 
positive and CMV PCR was 330 copy/ml, and ganci-
clovir was initiated. Funduscopic examination for 
CMV infection was normal. The liver biopsy revealed 
giant cell formation with canalicular and hepatocel-
lular cholestasis, without any evidence of CMV 
involvement. Immunohistochemical examination 
with MDR3 staining excluded the diagnosis of pro-
gressive familial intrahepatic cholestasis type 3. The 
patient was diagnosed to have GCH-AIHA condition, 
and anti-nuclear and anti-liver kidney microsomal 
antibodies were found to be negative. Serum ferri-
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Table 1. Characteristics of patients with GCH and AIHA
  Case 1  Case 2  Case 3
Onset of AIHA (mo)  2   1   11 
Onset of hepatitis (mo)  8   3   15 
CMV status  +  +  -
Ganciclovir therapy  +  +  -
Serum 32078,  325  93
ferritin (ng/ml)  (4858)* 
Treatment Methylprednisolone  Ursodeoxycholic  Methylprednisolone
 IVIG  acid  Azathioprine
 Azathioprine  Cholestyramine  Rituximab
  Rituximab     Ursodeoxycholic acid
 Cholestyramine
 Omega-3
Additional problem  High serum IgA   High serum IgA,   Transient
  and IgM levels  IgG and IgM levels;  hypogammaglobulinemia
    G6PDH deficiency  of infancy
Outcome  Died at 17 mo  Died at 8 mo  Alive at 35 mo
* Initial serum ferritin was measured as 32078 ng/ml and subsequently dropped to 4858 ng/ml by the second week of admission.
AIHA: Autoimmune hemolytic anemia; mo: month; CMV: Cytomegalovirus; IVIG: Intravenous immunoglobulin; G6PDH: Glucose 6-phosphate dehydrogenase.tin was measured as 325 ng/ml. Interestingly, the 
patient was found to have additional glucose 6-phos-
phate dehydrogenase deficiency. He was placed on 
ursodeoxycholic acid and cholestyramine and was 
discharged for close follow-up; however, it was 
learned that he died in the 2nd month of discharge 
in a local hospital.
Case 3 
An 11-month-old male presented initially to 
another center with pallor and was found to have 
Hb of 4.1 g/dl with 4+ direct Coombs’ test. It was 
learned that methylprednisolone 10 mg/kg/day had 
been initiated and the dose was tapered off subse-
quently; however, he had two more attacks during 
periods of dose reduction of steroid treatment and 
needed doses as high as 20 mg/kg/day for hemoly-
sis control. At 15 months of age, while on 2 mg/kg/
day methylprednisolone treatment, he developed 
vomiting and diarrhea and presented to our center. 
The family history was unremarkable excluding the 
second- degree consanguinity between parents. He 
had three healthy older siblings. The physical exam-
ination revealed a jaundiced boy with liver palpable 
2 cm subcostally on the midclavicular line. The 
hemogram revealed Hb: 7.9 g/dl, Hct: 23.1%, WBC: 
12.1x109 /L, thrombocyte: 147x109 /L, MCV: 93.7 fl, 
and RDW: 18.6. Reticulocytes were 4%. Direct 
Coombs’ test was positive. The liver function tests 
revealed AST: 770 IU/L, ALT: 1225 IU/L, GGT: 141 
IU/L, total bilirubin: 3.95 mg/dl, direct bilirubin 2.36 
mg/dl, total protein: 5.31 g/dl, and albumin: 3.33 g/
dl. aPTT and PT (INR) were 30.0 sec (25-40) and 
0.96 (0.75-1.5), respectively. Serum haptoglobulin 
level was <5.83 mg/dl (36-195). Viral serologies for 
Epstein-Barr virus (EBV), hepatitis A, hepatitis B, 
hepatitis C, hepatitis E, human immunodeficiency 
virus (HIV) and parvovirusB19 were negative, 
whereas the patient was immune for hepatitis B 
related to prior immunization, and he was IgM 
negative and IgG positive for CMV infection. Serum 
ferritin was 93 ng/ml. Anti-mitochondrial, anti-
smooth muscle and anti-liver kidney microsomal 
antibodies were negative. Serum IgA, IgG and IgM 
were measured as 81 mg/dl (30-107), 420 mg/dl 
(605-1430) and 96 mg/dl (66-228), respectively, and 
the low IgG level for age was considered as tran-
sient hypogammaglobulinemia of infancy. 
Ursodeoxycholic acid was initiated and steroid 
dose was increased up to 10 mg/kg/day. Liver biop-
sy revealed fibrosis in the portal areas, giant cell 
transformation of hepatocytes, intracellular cho-
lestasis, sinusoidal dilatation, and focal areas of 
extramedullary hematopoiesis, with no evidence of 
hemosiderin or copper accumulation. Azathioprine 
was initiated in addition to steroid treatment. During 
the course, because of the frequent attacks of 
Coombs’-positive hemolytic anemia, rituximab (375 
mg/m2/week, for four weeks) was started at the 6th 
month of azathioprine, at the age of 24 months. 
Steroid was gradually tapered off and azathioprine 
was continued. This patient is currently alive, free of 
transfusion, with negative direct Coombs’ test and 
normal liver function tests, after a follow-up of 18 
months and completion of four weekly doses of 
rituximab. 
Written informed consent was obtained from 
patients.
Discussion
Although GCH-AIHA association was reported 
more commonly among infants, there are rare 
reports of late-onset cases, such as in an 18-year-old 
male who survived after orthotopic liver transplan-
tation [3]. In our series of cases, the patients pre-
sented between 1 and 11 months of age with AIHA, 
which preceded hepatitis by 2-6 months. Case 1 
and 3 received immunosuppressive treatment prior 
to the development of overt hepatitis, which could 
not prevent the development of the subsequent dis-
ease. The presence of consanguinity between par-
ents of all three patients may indicate an underlying 
inherited immunological defect predisposing these 
children to this peculiar association.
Giant cell hepatitis (GCH) associated with AIHA 
has been reported to have mortality rates as high as 
approximately 50% [13], and this high mortality has 
been attributed not only to the severe liver failure or 
uncontrollable anemia, but also to sepsis related to 
the aggressive use of immunosuppressive drugs 
[6,8,13,17]. As our cases and the literature data indi-
cate, although this condition carries a high mortali-
ty, the clinical spectrum shows some diversity in 
severity and may respond to steroid alone or in 
combination with azathioprine [9,14,15]. However, 
there are other reports in which the cases were 
unresponsive to immunosuppressive therapies and 
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of liver transplantation also show variable out-
comes, including very early (even within weeks) 
recurrence of the disease in the transplanted liver 
[13,17] as well as survival after transplantation [2,3]. 
The post-transplant survivors may also have benefit-
ed from the immunosuppressants used during the 
post-transplantation period. 
Recently, there have been promising results with 
monoclonal antibodies including rituximab or alem-
tuzumab therapy, which may decrease the require-
ment for transplantation [1,4,5]. The good results 
with rituximab and recurrence of disease after liver 
transplantation in the transplanted liver may indi-
cate a circulating as-yet undetermined antibody in 
these patients. Additionally, the serum immuno-
globulin abnormalities in our study group may also 
indicate an immune dysregulation in these patients. 
All three of our patients were negative for the auto-
immune markers. Two of the patients were CMV 
PCR-positive and received ganciclovir treatment; 
however, no accompanying viral agent could be 
demonstrated in Case 3. This finding may indicate 
an autoimmune activation and loss of self-tolerance 
in these patients related to some infections. 
Camerero Salcés et al. [16] also reported associated 
CMV infection with this condition.
The presence of high conjugated bilirubinemia, 
in addition to a less prominent unconjugated biliru-
binemia in these patients may be attributed more to 
the hepatitis than hemolytic anemia in these 
patients. Additionally, the unconjugated bilirubin 
may have caused inspissated bile syndrome, which 
could also explain the conjugated bilirubinemia in 
these patients. 
Both Cases 1 and 3 had received less than 10 
packed erythrocyte transfusions prior to serum fer-
ritin measurement and liver biopsy. The serum fer-
ritin level was extremely high in Case 1 (Table 1) 
and the liver biopsy also exhibited hemosiderin 
accumulation. The rapid decline in serum ferritin 
from 32078 ng/ml to 4858 ng/ml after intensification 
of immunosuppressive treatment may indicate that 
the high serum ferritin level in this patient reflects 
the severity of inflammation. Hyperferritinemia may 
also be related to the prior transfusions and may 
also exacerbate the underlying hepatitis in the pres-
ence of iron accumulation in the liver. The serum 
ferritin level of Case 3 was 93 ng/ml, without any 
evidence of hemosiderin accumulation in the liver 
biopsy, and this patient was the only one to survive. 
Serum ferritin was measured as 325 ng/ml in Case 
2, without any evidence of iron accumulation in the 
liver. The previously reported case of Akyildiz et al. 
[3] was reported to have a pre-transplantation 
serum ferritin level of 3236 ng/ml and their patient 
survived after liver transplantation. These findings 
may indicate that lower serum ferritin levels can 
predict the responsiveness to immunosuppressive 
treatment, and as a consequence, the better out-
come in some patients; it may also explain the 
clinical heterogeneity of the GCH-AIHA. Case 1, who 
had very high serum ferritin levels, had a poor 
course in spite of immunosuppression, whereas 
Case 3, who had lower initial serum ferritin levels, 
responded well to treatment. However, Case 2, who 
had a moderate increase in ferritin, did not have the 
opportunity to receive immunosuppressive treat-
ment; thus, it is not possible to draw a conclusion 
about the relationship between his serum ferritin 
and the treatment response-outcome. Additionally, 
CMV infection might also have contributed to the 
higher serum ferritin levels and poorer outcomes in 
Cases 1 and 2, compared to the CMV-negative Case 
3. While the sample size is limited for making a 
definitive conclusion, if this observation is con-
firmed with further studies with increased numbers 
of patients, serum ferritin may be used to predict 
which patients may benefit from immunosuppres-
sives and those which may require more aggressive 
approaches, including earlier transplantation. This 
would also help to decrease the deaths related to 
the prolonged use of immunosuppressives.
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